Literature DB >> 10382927

Nerve root sleeve injections in patients with failed back surgery syndrome: a comparison of three solutions.

J Devulder1, P Deene, M De Laat, M Van Bastelaere, G Brusselmans, G Rolly.   

Abstract

OBJECTIVE: To evaluate outcome in patients with failed back surgery syndrome treated with nerve root sleeve injections. DESIGN AND PATIENTS: An open, nonblinded, randomized study on 60 patients with documented fibrosis in fewer than three nerve roots.
INTERVENTIONS: After random selection, 20 patients were injected with 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A), another 20 were treated with 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (Depo Medrol) per nerve root (group B), and a third group was treated with bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C). The volume of each injection was 2 ml. The injections were given twice at an interval of 1 week. OUTCOME MEASURES: The patients were evaluated on a verbal pain rating scale 1, 3, and 6 months after the second injection. The Kruskal-Wallis test was used to detect statistically significant differences among the three groups, and the analysis was refined with the Friedman test. RESULTS AND
CONCLUSIONS: Overall, although injections induced analgesia at 1 month, these effects were reduced at 3- and 6-month follow-ups. No statistical differences were found between the three treatment groups (after 1 month, p = 0.71; after 3 months, p = 0.69; after 6 months, p = 0.66. The Friedman test showed a significant decrease in treatment score as a function of time in groups B and C (p = 0.015) but not in group A (p = 0.074). Corticosteroids seem responsible for the last phenomenon.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382927     DOI: 10.1097/00002508-199906000-00010

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  9 in total

Review 1.  Failed back surgery syndrome.

Authors:  V C Anderson; Z Israel
Journal:  Curr Rev Pain       Date:  2000

Review 2.  Combination pharmacotherapy for the treatment of neuropathic pain in adults.

Authors:  Luis Enrique Chaparro; Philip J Wiffen; R Andrew Moore; Ian Gilron
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 3.  Access routes and reported decision criteria for lumbar epidural drug injections: a systematic literature review.

Authors:  Gustav Andreisek; Maja Jenni; Dominic Klingler; Maria Wertli; Marina Elliott; Erika J Ulbrich; Sebastian Winklhofer; Johann Steurer
Journal:  Skeletal Radiol       Date:  2013-08-31       Impact factor: 2.199

4.  Failed back surgery syndrome: a new strategy by the epidural injection of MESNA.

Authors:  M Carassiti; A Di Martino; A Centonze; C C Quattrocchi; A Caldaria; F Agrò; V Denaro
Journal:  Musculoskelet Surg       Date:  2017-11-02

5.  Neck and Back Pain in the Elderly.

Authors:  Steven N. Kalkanis; Lawrence Borges
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

6.  Effects of Caudal Epidural Dexmedetomidine on Pain, Erythrocyte Sedimentation Rate and Quality of Life in Patients with Failed Back Surgery Syndrome; A Randomized Clinical Trial.

Authors:  Masoud Hashemi; Payman Dadkhah; Mehrdad Taheri; Mahshid Ghasemi
Journal:  Bull Emerg Trauma       Date:  2019-07

7.  The additional effect of hyaluronidase in lumbar interlaminar epidural injection.

Authors:  Sang Beom Kim; Kyeong Woo Lee; Jong Hwa Lee; Min Ah Kim; Byung Hee Kim
Journal:  Ann Rehabil Med       Date:  2011-06-30

Review 8.  Neuropathic Pain after Spinal Surgery.

Authors:  Jae Hwan Cho; Jae Hyup Lee; Kwang-Sup Song; Jae-Young Hong
Journal:  Asian Spine J       Date:  2017-08-07

9.  Short-term results after local application of steroids and anesthetics in patients with painful spine conditions.

Authors:  Narcisa Vavra Hadziahmetovic; Damir Aganovic; Aldijana Kadic; Mirza Biscevic
Journal:  Med Arch       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.